Breaking barriers in the first-line Helicobacter pylori treatment: Chinese multicenter trial validates vonoprazan-based triple therapy

Table 1 Surface under the cumulative ranking of the Helicobacter pylori eradication rate first-line treatment regimens analyzed in network meta-analyses, (%)

Ref.	Therapies	SUCRA
		Overall data	West	East Asia	West Asia
Rokkas et al[11], 2021	VPZ-triple therapy	92.4		94.1
	Bismuth quadruple therapy	33.2	44.7	50.5	2.4
	AMOX-dual therapy	4.7	15.2	15.2	31.5
Malfertheiner et al[12], 2022	VPZ-triple therapy1	89.6	80.6
	VPZ-dual therapy1	80.3	77.2
	Bismuth quadruple therapy1	78.4	82
	AMOX-dual therapy1	65.6	65.7
Liu et al[13], 2023	VPZ-triple therapy	92.6
	VPZ-triple therapy2	89.3
	VPZ-dual therapy	56.3
	VPZ-dual therapy2	56.3
Huang et al[14], 2024	VPZ-triple therapy/14 days	78.2
	VPZ-triple therapy/7 days	43.2
	VPZ-dual therapy/14 days	61.7
	VPZ-dual therapy/7 days	37.2
Jiang et al[15], 2024	VPZ-triple therapy/14 days	90.4
	VPZ-dual therapy/14 days	51.0

¹Data presented as pooled (weighted) eradication rate.

²Surface under the cumulative ranking values in patients with clarithromycin resistant strains.

SUCRA: Surface under the cumulative ranking; VPZ: Vonoprazan; AMOX: Amoxicillin.